{"id":"NCT01408576","sponsor":"UCB Pharma","briefTitle":"Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus","officialTitle":"A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2016-02","completion":"2016-02","firstPosted":"2011-08-03","resultsPosted":"2018-10-03","lastUpdate":"2018-10-03"},"enrollment":1250,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Lupus Erythematosus"],"interventions":[{"type":"DRUG","name":"Epratuzumab","otherNames":[]},{"type":"DRUG","name":"Epratuzumab","otherNames":[]}],"arms":[{"label":"Epratuzumab 600 mg per week","type":"EXPERIMENTAL"},{"label":"Epratuzumab 1200 mg every other week","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)","primaryOutcome":{"measure":"Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)","timeFrame":"During the treatment period (through Week 96)","effectByArm":[{"arm":"Enrollment Cohort 1 Epratuzumab 600 mg Per Week (ES)","deltaMin":26,"sd":null},{"arm":"Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (ES)","deltaMin":45,"sd":null},{"arm":"Enrollment Cohort 2 Epratuzumab 600 mg Per Week (ES)","deltaMin":25,"sd":null},{"arm":"All Epratuzumab 600 mg Per Week","deltaMin":51,"sd":null},{"arm":"All Subjects","deltaMin":96,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":228,"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","Czechia","Estonia","France","Germany","Hong Kong","Hungary","Israel","Italy","Lithuania","Mexico","Poland","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":244},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Headache","Nausea","Nasopharyngitis"]}}